Nutrient transporters in cancer: relevance to Warburg hypothesis and beyond.

By V. Ganapathy, M. Thangaraju, P. Prasad. Pharmacology and Therapeutics, 2009

707 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

SLC Transporters as Therapeutic Targets: Emerging Opportunities (2015, positive): “However, inhibition of key nutrient transporters, such as the glucose transporters of the SLC2 and SLC5 families, amino acid transporters of the SLC7 family and lactate transporters of the SLC16 family, may be a reasonable approach for discovering new anticancer drugs 133 .”
Glucose transporters in the 21st Century. (2010, background): “Although many more examples could be mentioned, a second and inverse application reflects the observation that Glut1 is frequently upregulated during oncogenesis in many different tissue types (13), a process that is probably essential for tumors to grow beyond a size limited by their glycolytic cap”
From the gut to the peripheral tissues: the multiple effects of butyrate (2010, positive): “But in the presence of butyrate, expression of SLC5A8 is again enhanced and it increases cell apoptosis (75) .”
Reactive oxygen species in cancer (2010, background): “Normal cells switch to anaerobic glycolysis only when adequate oxygen supply is not available and mitochondrial function is suppressed [198].”